Shareholders of Shanghai Bio-heart Biological Technology (HKG:2185) will meet Feb. 13 to vote on the proposed 155.6 million yuan capital injection into unit Zhejiang Bioheart Medical Equipment, a Thursday bourse filing said.
The parties had agreed on earlier in January that Jiaxing Guojian Baixin Equity Investment Partnership Enterprise would make the investment in exchange for a 45.3208% stake in Zhejiang Bioheart.
Price (HKD): $1.55, Change: $+0.010, Percent Change: +0.65%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。